Wortmannin (KY 12420)

Catalog No.S2758 Synonyms: SL-2052, BRN 0067676, NSC 627609

For research use only.

Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

Wortmannin (KY 12420) Chemical Structure

CAS No. 19545-26-7

Selleck's Wortmannin (KY 12420) has been cited by 257 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Wortmannin (KY 12420, SL-2052, BRN 0067676, NSC 627609) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjPc5dYOi53IN88US=> Mnv3NU01KGR? NWfQfGM6TE2VTx?= M4e1bYVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUCzPFMoRjJ3NEmwN|g{RC:jPh?=
H1703 NV;QVppQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjsOmczNjVizszN NHfrWG0yNTRiZB?= Mk[xSG1UVw>? NV\2SVFE\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? MkCxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUCzPFMoRjJ3NEmwN|g{RC:jPh?=
HUVECs MUDDfZRwfG:6aXPpeJkhSXO|YYm= Ml\ZNVAxKG6P NG\WfZUzPCCq Mk[zZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NULFcnoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OVAyQDZpPkK1OFUxOTh4PD;hQi=>
APRE-19 M2\DcWFxd3C2b4Ppd{BCe3OjeR?= NGKx[JA2KM7:TR?= MVWyOEBp NFnzV3Bi[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN{OU[xO{c,OjV|Mkm2NVc9N2F-
MDA-MB-231 MYXBdI9xfG:|aYOgRZN{[Xl? NVXJcGl{OcLizszNxsA> NUL5Sm1WPDhiaB?= MmDrSG1UVw>? MV\k[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyMEmzNkc,OjV|MEC5N|I9N2F-
MCF7 NXLIemJXTnWwY4Tpc44hSXO|YYm= NX3VbpZ[OTByIH7N Mo\lNlQhcA>? MUjlcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5MkW1O{c,OjVzN{K1OVc9N2F-
HT-29  NVnqVWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\kUoIyNjYEoNM1US=> M4fDeFk3KGh? MnfT[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzMkGyN{c,OjVyMUKxNlM9N2F-
MO59K  MnO3R5l1d3SxeHnjbZR6KEG|c3H5 M3jySVXDqM7:TR?= M{i5Rlch\A>? NWnhWmt5TE2VTx?= MkDs[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NYTmT3dnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVM2PjFpPkK0PVU{PTZzPD;hQi=>
MO59J MkXMR5l1d3SxeHnjbZR6KEG|c3H5 M1ixVlXDqM7:TR?= M3vFXFch\A>? M3\RXGROW09? MX\lcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? M3vPeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWzOVYyLz5{NEm1N|U3OTxxYU6=
MO59K  M3jXdmFxd3C2b4Ppd{BCe3OjeR?= NHj5XJMyOCEQvF2= MXWyOEBp M2XXcWROW09? NXXMbYJ5cW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw M1fsdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWzOVYyLz5{NEm1N|U3OTxxYU6=
MO59J MXjBdI9xfG:|aYOgRZN{[Xl? MnS4NVAh|ryP Mnn0NlQhcA>? MXzEUXNQ MnPubY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv NXT5elVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVM2PjFpPkK0PVU{PTZzPD;hQi=>
HepG2 MXzGeY5kfGmxbjDBd5NigQ>? NFnHe4oyODBibl2= NEHwT|kxNjViaB?= NFu1TpdFVVOR Mnz3Zoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> Mlu3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NkOzOVAoRjJ2OE[zN|UxRC:jPh?=
A549  NHXV[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjvVmY{KML3TdMg NIrUdXAzKGh? NHzDOHR{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w NGi0V3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi0O|g3Oyd-MkS4OFc5PjN:L3G+
A549  M2LK[WZ2dmO2aX;uJGF{e2G7 MkHYNVDDqM7:bdMg M3vGelE3KGh? M2K0eGROW09? M{XPO41w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> M1S2clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OECyNVEyLz5{NEiwNlEyOTxxYU6=
SK-N-LO MXvGeY5kfGmxbjDBd5NigQ>? NIS2NpkyODBibl2= MkXBNE42KGh? NEPlVm1l\WO{ZXHz[ZMhfGinIIP0bY12dGGwdDDl[oZm[3S|IH;mJI1wenCqaX7lJI9vKEGtdDDwbI9{eGixconsZZRqd25? NIOyT489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1OFYxPid-MkS2OVQ3ODZ:L3G+
HL-60 NHzE[FFHfW6ldHnvckBCe3OjeR?= NV;aeXZUOC5zwrFOwG0> NWDxTmN1PzJiaB?= M4n3[YJtd2OtczDkZZNifGmwaXKtbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvci=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{K3N{c,OjR4MEeyO|M9N2F-
HepG2  MoSwSpVv[3Srb36gRZN{[Xl? NYLZZY1YOjByIH7N M2q0VFAvPSCq NYDjTpdE[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3M{WxPVIoRjJ2NUO1NVkzRC:jPh?=
H520 MY\GeY5kfGmxbjDBd5NigQ>? NWfiZ5Q4OTEEoN88US=> NVzBfoo3OSCq NWe0[YJLTE2VTx?= NVnjSYR4\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ Mli1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NEe5N|UoRjJ2NES3PVM2RC:jPh?=
H1975 MmfaSpVv[3Srb36gRZN{[Xl? NHfzfJIyOMLizszN NYP3bmw4OSCq M3jnNWROW09? NES3PHRl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> M2rqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NES3PVM2Lz5{NES0O|k{PTxxYU6=
MG-63 MUDBdI9xfG:|aYOgRZN{[Xl? Mkm1NVAhyrWP NY\GS|hVOTJiaB?= NIrCWHBmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OEOwNUc,OjR|NUizNFE9N2F-
5637 MY\BdI9xfG:|aYOgRZN{[Xl? MWGxNOKh|ryP MljmOFAhdWmw MnG2doV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv NXz5W4xzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN|M5PjhpPkK0N|M{QDZ6PD;hQi=>
HEK-293 M4n2VWZ2dmO2aX;uJGF{e2G7 NUDCdoVQOTVybl2= NVfodYl3OTZiaB?= NGfmXnRFVVOR MYrk[YNz\WG|ZYOgR3JVKGGldHn2bZR6 NUnRXJVpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQ{PjZpPkK0N|I1OzZ4PD;hQi=>
SW480  MWPGeY5kfGmxbjDBd5NigQ>? MnvDNVUxdk1? NUKyUVFvOjBiaB?= MVTEUXNQ MoLOdoVlfWOnczDj[YxtfWyjcjDhZ4N2dXWuYYTpc44hd2ZizsKtZ4F1\W6rbh?= NVGwUllKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQ{PjZpPkK0N|I1OzZ4PD;hQi=>
HepG2 NV;GVWEyTnWwY4Tpc44hSXO|YYm= M{faWlExOCCwTR?= M3PG[FI1KGh? NEXqUZZifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= MkS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NVAoRjJ2Mkm3OVExRC:jPh?=
HCT 116  NHXuNFZHfW6ldHnvckBCe3OjeR?= MoHqNVAxKG6P MWKyOEBp NFLTb4hifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NVAoRjJ2Mkm3OVExRC:jPh?=
BEL/FU MVPGeY5kfGmxbjDBd5NigQ>? MnPHNUBuVQ>? MmXZNlQhcA>? NUTpSolG\GWlcnXhd4V{KHC{b4TlbY4hdGW4ZXzzJI9nKHSqZTDQTVNMN0GtdDDwZZRpf2G7 NWjkZnQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyN|IxQTlpPkK0NlMzODl7PD;hQi=>
Huh7  MofoSpVv[3Srb36gRZN{[Xl? MV6zxsDPxE1? MUKxJIg> NVjKSphbemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF6NEG5Okc,OjRzOESxPVY9N2F-
A-375 MlTRRZBweHSxc3nzJGF{e2G7 NVHUb49mPC96IN88US=> MXmyOEBp M1PHRYVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= M2X5TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzNVc{Lz5{NEGxN|E4OzxxYU6=
A-375-TS  NXq5OmZISXCxcITvd4l{KEG|c3H5 NV;zRpI4PC96IN88US=> MU[yOEBp NHu1[2tmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{G3N{c,OjRzMUOxO|M9N2F-
Mel-HO NGfpe2pCeG:ydH;zbZMhSXO|YYm= NFT3T3Q1NzhizszN M2rw[VI1KGh? Mnft[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MoXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUOxO|MoRjJ2MUGzNVc{RC:jPh?=
Mel-HO-TS M4PzcWFxd3C2b4Ppd{BCe3OjeR?= NUTGN4FuPC96IN88US=> NIm3S40zPCCq NUDOV|lH\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzM{G3N{c,OjRzMUOxO|M9N2F-
MeWo NFOxfmtCeG:ydH;zbZMhSXO|YYm= M17TVFQwQCEQvF2= MXGyOEBp MWTlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li M2jUdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzNVc{Lz5{NEGxN|E4OzxxYU6=
Mel-2a M3fVUmFxd3C2b4Ppd{BCe3OjeR?= M1LvPVQwQCEQvF2= NF7LUFczPCCq NW[5XoFL\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUOxO|MoRjJ2MUGzNVc{RC:jPh?=
MDA-MB-231 NXjsTYJrTnWwY4Tpc44hSXO|YYm= M2\PVFDjiJN2MECgcm0> MkP4OEBp MXPzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjlyNkK1PUc,OjJ7ME[yOVk9N2F-
MDA-MB-231 NWLxb29CTnWwY4Tpc44hSXO|YYm= NXn0[ldMPDByIH7N MXK0JIg> MkWz[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjlyNkK1PUc,OjJ7ME[yOVk9N2F-
Jurkat NVjXS3IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jqOVAvOjVvMT6yOUDPxE1? MVuyOE81QCCq Mn:4SG1UVw>? MVPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd3N{G4OUc,OTl5NUexPFU9N2F-
Namalwa MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTIRoMxNjJ3LUGuNlUh|ryP NU\YeWQ{OjRxNEigbC=> MUjEUXNQ Ml3VbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? MlXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUexPFUoRjF7N{W3NVg2RC:jPh?=
Jurkat MVjBdI9xfG:|aYOgRZN{[Xl? NXe4UW03OC5{NT2xMlI2KM7:TR?= M4HYZVI1NzR6IHi= MVzEUXNQ MlnybY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NWnLTndbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVcyQDVpPkG5O|U4OTh3PD;hQi=>
Namalwa Mlv5RZBweHSxc3nzJGF{e2G7 NUWwVVZsOC5{NT2xMlI2KM7:TR?= NV7vXJdbOjRxNEigbC=> NUjEd2hzTE2VTx?= MUPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= M{\SclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{W3NVg2Lz5zOUe1O|E5PTxxYU6=
K562 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPLNlQhcA>? NHfSOnVKSzVyPUK1xtExNjF2IH7N MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ4MkO2NUc,OTl4NkKzOlE9N2F-
SW1990 NHfiPWRHfW6ldHnvckBCe3OjeR?= Mk[xNE4xOS1zIN88US=> NIXBTFEyKGh? NYTkOpNscW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4OUCyNEc,OTl2NkmwNlA9N2F-
RT112  MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXnV2lCOTEEoN88US=> NHLlWlUzPCCq MlPkSG1UVw>? M{\aPIRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MlroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh5OEe4N|IoRjF6N{i3PFMzRC:jPh?=
MHG-U1 M3nCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n6clExyqEQvF2= M3rvTFI1KGh? MYPEUXNQ M{SzV4Rm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ NXTYd5hwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3PFc5OzJpPkG4O|g4QDN{PD;hQi=>
SMMC-7721 NG[zTFlCeG:ydH;zbZMhSXO|YYm= MoLnNlAxyqCwTR?= M3X6S|I1KGh? NF3EV|NqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| NGTofI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1O|E6OSd-MUe1OVcyQTF:L3G+
SMMC-7721 NWntdph[TnWwY4Tpc44hSXO|YYm= MXmyNFDDqG6P MWiyOEBp NGP0RZV2eC2{ZXf1cIF1\XNizsKxMFRIXDFiZYjwdoV{e2mxbh?= NITj[nY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W1O|E6OSd-MUe1OVcyQTF:L3G+
HeLa NELac2ZHfW6ldHnvckBCe3OjeR?= M1L0TFExOMLibl5CpC=> NUnTTodMOSCq MkflZYx1\XK|IITo[UBud3KyaH;sc4d6KG:oIITo[UB1emGwc3\ldpJqdiC{ZXP5Z4xqdmdiY3;tdIFzfG2nboS= NEfYXI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki5NFkyPSd-MU[4PVA6OTV:L3G+
MRC5VI NFHuVYVHfW6ldHnvckBCe3OjeR?= M{XjeVEzNjVibV2= NYeweGt7OC53IHi= MXnEUXNQ NX;nUGx{[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ{MkezPVQoRjF4MkK3N|k1RC:jPh?=
AT5BIVA MkXVSpVv[3Srb36gRZN{[Xl? MlzENVIvPSCvTR?= M{PFblAvPSCq Ml;TSG1UVw>? M4fQZYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NX3SWFBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[yNlc{QTRpPkG2NlI4Ozl2PD;hQi=>
M059J NH3xfWxHfW6ldHnvckBCe3OjeR?= MVuxNk42KG2P MWewMlUhcA>? MVLEUXNQ NXvyUIFK[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? M2PwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4MkK3N|k1Lz5zNkKyO|M6PDxxYU6=
HeLa MkPSSpVv[3Srb36gRZN{[Xl? MmnTNVIvPSCvTR?= NHPXV|gxNjViaB?= M3vEVWROW09? M{\1WoFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ{MkezPVQoRjF4MkK3N|k1RC:jPh?=
N2a M3zTVWFxd3C2b4Ppd{BCe3OjeR?= MoDLNE4yNTFyIN88US=> MlXINkBp NVXvNFlLcW6mdXPld{Bl\WO{ZXHz[YQh[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NVjsTmNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4OFI4PjdpPkG1PFQzPzZ5PD;hQi=>
Jurkat  M4XhRWtqdmG|ZTDBd5NigQ>? NW\wWYw6UUN3MDDv[kAzPCCwTR?= M2XWU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3Nk[0OVE6Lz5zNU[2OFUyQTxxYU6=
Sf9 MojtSpVv[3Srb36gZZN{[Xl? MoLmTY5pcWKrdHnvckBw\iCqdX3hckBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[XluIFnDOVAhRSByLkCxNkDPxE1w MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
HeLa MXnGeY5kfGmxbjDhd5NigQ>? MUDJcohq[mm2aX;uJI9nKEG[LUe1NFMh[mmwZHnu[{B1dyC{ZXPvcYJqdmGwdDDQcIs{KGW6cILld5Nm\CCrbjDI[WxiKGOnbHzzJIJ6KFenc4Tldo4h[myxdDygTWM2OCB;IECuNFQ6KM7:TT6= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF|NUK0PEc,OTdzM{WyOFg9N2F-
HeLa NEjteoxHfW6ldHnvckBie3OjeR?= Mkj5Rolv\GmwZzDh[oZqdmm2eTDmc5IhTE6DIHTldIVv\GWwdDDwdo91\WmwIHvpcoF{\SCrc3;sZZRm\CCocn;tJGhmVGFiY3XscJM8KFKjbnflJIl{KDJyLUGyNEwhU2liPTCwMlEzKM7:TT6= MnjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O|AoRjF3NkW4PFcxRC:jPh?=
HeLa NU[1bnU6TnWwY4Tpc44h[XO|YYm= MYjCbY5lcW6pIHHm[olvcXS7IH\vdkBRcG:|cHjheIllgWyrbn;zbZRwdCB|LXvpcoF{\SCrc3;sZZRm\CCocn;tJGhmVGFiY3XscJM8KFKjbnflJIl{KDJyLUGyNEwhU2liPTCwMlEzKM7:TT6= M1myOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
A549 MYLGeY5kfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKFCua{OgbY4hcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyClYYPlbY4he3Wkc4TyZZRmKHCqb4PwbI9zgWyjdHnvckBjgSCZZYP0[ZJvKGKub4SsJGlEPTBiPTCwMlIzKM7:TT6= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF|NUK0PEc,OTdzM{WyOFg9N2F-
A549 NHTTW4xCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NIrJOXk1QCCqcoO= NYfrOWM6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNVEvPCEQvF2u NHnadVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[zNFg6PCd-MUi2N|A5QTR:L3G+
GM00637 NXn4bY5rTnWwY4Tpc44h[XO|YYm= NFTmcFQyKHWP MXfJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IGDsb|Mh\XiycnXzd4VlKGmwIHj1cYFvKEePMEC2N|ch[2WubIOgZZQhOSC3TTDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCyNUOgd4VzcW6nLUKwJJBpd3OyaH;yfYxifGmxbh?= MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzM{WyOFgoRjF5MUO1NlQ5RC:jPh?=
MDA-MB-231 NV3SRVVsTnWwY4Tpc44h[XO|YYm= NGfUb3AyKHSxIEGwJJVO NFLMfJkzPCCqcoO= MkHtTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KDFidH:gNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= NEPPbYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiyPFI5Pid-MkS4NlgzQDZ:L3G+
HeLa MV7GeY5kfGmxbjDhd5NigQ>? MVSxNFAhdk1? NIHIV2kyOCCvaX7z NH;BNmlKdmirYnn0bY9vKG:oIGDJN2shcW5iaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTUeILYP0bY12dGG2ZXSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVNEezJIF1KDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFExKG2rboOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJI1m[XO3cnXkJIFnfGW{IEWgcYlveyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NELVRXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEO4NFg3PSd-M{CzPFA5PjV:L3G+
HeLa NIXlWGZHfW6ldHnvckBie3OjeR?= NUmzU2F2OTByIH7N MUCxNEBucW6| Ml;ZTY5pcWKrdHnvckBw\iCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVITi2|dHnteYxifGWmIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhXDNyODDheEAyODBibl2gdJJmcW6ldXLheIVlKG[xcjCxNEBucW6|IH\vcIxwf2WmIHL5JGVITiC|dHnteYxifGmxbjDt[YF{fXKnZDDh[pRmeiB3IH3pcpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MoTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB|OEC4OlUoRjNyM{iwPFY2RC:jPh?=
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3 25344912
Immunofluorescence DNMT1 24001151
Growth inhibition assay Cell viability 25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol (from reference)

Animal Research:[11]
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.

Solubility (25°C)

In vitro

DMSO 85 mg/mL
(198.39 mM)
Water Insoluble
Ethanol Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Wortmannin (KY 12420) | Wortmannin (KY 12420) supplier | purchase Wortmannin (KY 12420) | Wortmannin (KY 12420) cost | Wortmannin (KY 12420) manufacturer | order Wortmannin (KY 12420) | Wortmannin (KY 12420) distributor